Business Description

Description
Incyte focuses on the discovery and development of small-molecule drugs. The firm's lead drug, Jakafi, treats two types of rare blood cancer and graft versus host disease and is partnered with Novartis. Incyte's other marketed drugs include rheumatoid arthritis treatment Olumiant (licensed to Lilly), and oncology drugs Iclusig (chronic myeloid leukemia), Pemazyre (cholangiocarcinoma), Tabrecta (lung cancer), and Monjuvi (diffuse large B-cell lymphoma). The firm's first dermatology product, Opzelura, was approved in 2021 for atopic dermatitis and 2022 for vitiligo. Incyte's pipeline includes a broad array of oncology and dermatology programs.
Name Current Vs Industry Vs History
Cash-To-Debt 102.97
Equity-to-Asset 0.76
Debt-to-Equity 0.01
Debt-to-EBITDA 0.03
Interest Coverage 282.67
Piotroski F-Score 5/9
0
1
2
3
4
5
6
7
8
9
Altman Z-Score 6.09
Distress
Grey
Safe
Beneish M-Score -2.42
Manipulator
Not Manipulator
WACC vs ROIC
WACC
ROIC
Name Current Vs Industry Vs History
6-1 Month Momentum % -39.47
12-1 Month Momentum % -39.47

Liquidity Ratio

Name Current Vs Industry Vs History
Current Ratio 3.47
Quick Ratio 3.43
Cash Ratio 2.76
Days Inventory 73.4
Days Sales Outstanding 66.03
Days Payable 175.86

Dividend & Buy Back

Name Current Vs Industry Vs History
3-Year Average Share Buyback Ratio -0.7
Shareholder Yield % 0.03

Financials (Next Earnings Date:2024-08-01 Est.)

MEX:INCY's 30-Y Financials
Income Statement Breakdown FY
No Enough Data
Balance Sheet Breakdown
No Enough Data
Cashflow Statement Breakdown
No Enough Data

Historical Operating Revenue by Business Segment

Historical Operating Revenue by Geographic Region

5-Step DuPont Analysis as of
No Enough Data

Guru Trades

See Details
To

Insider Trades

See Details
To

Peter Lynch Chart

Y-axis scale:
Interactive Chart
To

Performance

Dividend
Log
Bar
To

Annualized Return %  

Symbol
1 Week
1 Month
3 Months
6 Months
YTD
1 Year
3 Years
5 Years
10 Years

Total Annual Return %  

Symbol
2024
2023
2022
2021
2020
2019
2018
2017
2016
2015

Incyte Corp Executives

Details

Valuation Chart

Year:

Analyst Estimate

Key Statistics

Name Value
Revenue (TTM) (Mil MXN) 64,557.395
EPS (TTM) (MXN) 56.549
Beta -0.02
Volatility % 39.47
14-Day RSI 0
14-Day ATR (MXN) 0.123429
20-Day SMA (MXN) 986
12-1 Month Momentum % -39.47
52-Week Range (MXN) 986 - 1629
Shares Outstanding (Mil) 224.85

Piotroski F-Score Details

Year:
Component Result
Piotroski F-Score 5
Positive ROA
Positive CFROA
Higher ROA yoy
CFROA > ROA
Lower Leverage yoy
Higher Current Ratio yoy
Less Shares Outstanding yoy
Higher Gross Margin yoy
Higher Asset Turnover yoy

Incyte Corp Filings

Filing Date Document Date Form
No Filing Data

Incyte Corp Stock Events

Financials Calendars
Event Date Price(MXN)
No Event Data

Incyte Corp Frequently Asked Questions

What is Incyte Corp(MEX:INCY)'s stock price today?
The current price of MEX:INCY is MXN986.00. The 52 week high of MEX:INCY is MXN1629.00 and 52 week low is MXN986.00.
When is next earnings date of Incyte Corp(MEX:INCY)?
The next earnings date of Incyte Corp(MEX:INCY) is 2024-08-01 Est..
Does Incyte Corp(MEX:INCY) pay dividends? If so, how much?
Incyte Corp(MEX:INCY) does not pay dividend.

Press Release

Subject Date
No Press Release